Accessibility Statement

1. Commitment:
Sanofi is committed to providing digital solutions that are accessible to the widest possible audience, regardless of ability, disability, race, cultural background, gender, or technological requirements.

This accessibility statement applies to the dupixent.ca website.

2. Conformance Status:
The Web Content Accessibility Guidelines (WCAG) defines requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA.

This website is partially conformant with WCAG 2.2 Level AA, due to the limitations described below.

3. Known Limitations:
Despite our best efforts to ensure the accessibility of this website, there may be some limitations. Below is a description of known limitations and potential solutions. Please contact us if you observe an issue not listed below.

  • Forms — Form field labels: Some form fields may not have clearly associated or descriptive labels.
  • ARIA — ARIA attributes: Certain elements with ARIA roles may have invalid or missing attributes.
  • Forms — Form field labels: Some form fields may not have clearly associated or descriptive labels.
  • Contrast — Colour contrast ratio: Some elements do not meet the minimum thresholds and may be challenging for some people to view and distinguish.

4. Feedback and Contact:
Please contact us if you encounter accessibility barriers on this website. If you are unable to access any content or service, we will provide an accessible alternative or offer the content in another form.

5. Preparation Method:
This statement was prepared in June 2026.

6. Formal Complaints:
If you are not satisfied with our response to you, you are entitled to escalate a complaint to the national authority.    

DUPIXENT® and Sanofi logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2026 sanofi-aventis Canada Inc. All rights reserved.
MAT-CA-2501555E- 1.0 - 02/2026    Last updated: February 2026

Innovative Medicines Canada PAAB

Sanofi Regeneron

DUPIXENT® (dupilumab)

Important Note
This website is intended for educational purposes and is in no way intended to substitute for professional medical advice, to contradict medical advice given, or for medical care of any kind. As with any medication, speak to your doctor before using. Please review the Terms & Conditions before using this website. Your use of this website indicates your agreement to be bound by the Terms & Conditions.